Testing small molecule analogues of acanthocheilonema viteae immunomodulator ES-62 against clinically relevant allergens

Janicova, L. and Rzepecka, J. and Rodgers, D.T. and Doonan, J and Bell, K. and Lumb, F.E. and Suckling, C.J. and Harnett, M.M. and Harnett, W. (2016) Testing small molecule analogues of acanthocheilonema viteae immunomodulator ES-62 against clinically relevant allergens. Parasite Immunology, 38 (6). pp. 340-351. ISSN 0141-9838 (https://doi.org/10.1111/pim.12322)

[thumbnail of Janicova-etal-PI2016-testing-small-molecule-analogues-od-acanthocheilonema]
Preview
 Text. Filename: Janicova_etal_PI2016_testing_small_molecule_analogues_od_acanthocheilonema.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (3MB)| Preview

Abstract

ES-62 is a glycoprotein secreted by the filarial nematode Acanthocheilonema viteae that protects against ovalbumin (OVA)-induced airway hyper-responsiveness in mice by virtue of covalently attached anti-inflammatory phosphorylcholine (PC) residues. We have recently generated a library of Small Molecule Analogues (SMAs) of ES-62 based around its active PC moiety as a starting point in novel drug development for asthma, and isolated two compounds - termed 11a and 12b – that mirror ES-62’s protective effects. In the present study we have moved away from OVA, a model allergen, to test the two SMAs against two clinically relevant allergens – house dust mite (HDM) and cockroach allergen (CR) extract. We show that whereas both SMAs offer some protection against development of lung allergic responses to CR, in particular reducing eosinophil infiltration, only SMA 12b is effective in protecting against eosinophil-dependent HDM-induced allergy. These data therefore suggest that helminth molecule-induced protection against model antigens may not necessarily translate to clinically relevant antigens. Nevertheless, in the present study we have managed to demonstrate that it is possible to produce synthetic drug-like molecules based on a parasitic worm product that show therapeutic potential with respect to asthma resulting from known triggers in humans.

ORCID iDs

Janicova, L., Rzepecka, J., Rodgers, D.T., Doonan, J ORCID logoORCID: https://orcid.org/0000-0001-6933-4840, Bell, K., Lumb, F.E. ORCID logoORCID: https://orcid.org/0000-0001-9742-5125, Suckling, C.J., Harnett, M.M. and Harnett, W. ORCID logoORCID: https://orcid.org/0000-0001-9545-9401;
CORE (COnnecting REpositories)